Clinical trials: Renal Transplant Recipient
Heart Transplant Failure, Kidney Failure
DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Kidney failure is common in heart transplant recipients and is a major cause of morbidity and mortality. Sodium-glucose transporter 2 (SGLT2) inhibitors were developed as antidiabetics but were subsequently shown to reduce the…
- Trial name
- DAPARHT (NCT05321706)
- Testing
- Dapagliflozin 10 mg
- Where
- 6 sites in Netherlands, Norway and 1 more
- Volunteers
- 430 people
- Sponsor
- Oslo University Hospital
Kidney Transplantation
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants…
- Trial name
- ASTOUND (NCT02723591)
- Testing
- Tacrolimus, Tacrolimus immediate release
- Where
- 30 sites in United States
- Volunteers
- 599 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Transplant; Complications, Diabetes Mellitus, Type 2
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36).
- Trial name
- CREST-KT (NCT04906213)
- Testing
- Empagliflozin10Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Cytomegalovirus (CMV) Infection, Kidney Transplantation
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative…
- Trial name
- NCT03629080
- Testing
- HB-101 vaccine
- Where
- 25 sites in United States, Denmark and 4 more
- Volunteers
- 83 people
- Sponsor
- Hookipa Biotech GmbH
Renal Transplantation
Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction
Combined transplantation of kidney and bone marrow between HLA-matched sibling donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation of immunosuppressive therapy without kidney rejection.
- Trial name
- NCT05086003
- Testing
- Combined kidney and bone marrow transplantation
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Nephropathy, Opportunistic Viral Infection
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients.
- Conditions
- Nephropathy, Opportunistic Viral Infection, Polyoma Virus Nephropathy, BK Nephropathy
- Trial name
- TYPIK (NCT07347769)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative
To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Conditions
- C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative, Glomerulonephritis (IC-MPGN), Kidney Transplantation
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
Pharmacokinetics Study in de Novo Kidney Transplantation
Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients
The purpose of this study was to investigate if Tacrolimus Hexal® has similar pharmacokinetic properties compared to Prograf® in de novo renal transplant patients and whether the comparable exposure resulted in similar renal…
- Trial name
- Spartacus (NCT01649427)
- Testing
- Prograf, Tacrolimus Hexal
- Where
- 5 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Pre-kidney Transplant, Living Donor Kidney Transplantation
Proteinuria and Renal Perfusion in Renal Transplant Recipients
Cardiovascular disease remains one of the major cause of mortality in renal transplant recipients, with the rate of cardiac death 10-times higher than that of the general population.
- Conditions
- Pre-kidney Transplant, Living Donor Kidney Transplantation, Renal Perfusion, End Stage Renal Disease
- Trial name
- NCT06051812
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Hyperglycemia
Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients
This study aims to assess the effects of early basal insulin therapy in previously non-diabetic de novo kidney transplant patients in reducing the incidence of new onset diabetes in particular and abnormal glucose metabolism in…
- Trial name
- ITP-NODAT (NCT03507829)
- Testing
- Human insulin isophane, Humulin N (Eli Lilly), Standard of care, Insulin lispro, Humalog (Eli Lilly) in insulin pump
- Volunteers
- 263 people
- Sponsor
- Medical University of Vienna
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Anemia
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
This two arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic renal anemia.
- Trial name
- NCT00605345
- Testing
- Darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 21 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Renal Transplant Rejection
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
This study aims to compare outcomes in renal transplant recipients in the hispanic population based on their immunosuppressant regimens.
- Trial name
- NCT00983645
- Testing
- Prograf, Neoral
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Loma Linda University
Osteoporosis, Chronic Kidney Disease
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients.
- Trial name
- POSTOP (NCT01377467)
- Testing
- Denosumab (Prolia)
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Rudolf Wuethrich
Kidney Disease, Kidney Failure
Older Kidney Patient Optimisation Pretransplant
The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation.
- Conditions
- Kidney Disease, Kidney Failure, Frailty, Cognitive Impairment
- Trial name
- OK-POP (NCT07419945)
- Testing
- Kidney transplant-specific comprehensive geriatric assessment
- Volunteers
- 50 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Kidney Failure, Kidney Diseases
Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
This is a proof of concept, single center study for the donation of HCV-positive kidney to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent…
- Conditions
- Kidney Failure, Kidney Diseases, Hepatitis C
- Trial name
- NCT03623568
- Testing
- glecaprevir/pibrentasvir tablets
- Where
- United States
- Sponsor
- Raymond T. Chung, MD
Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant…
- Trial name
- NCT04006808
- Testing
- PED-HZ/su
- Where
- 31 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Renal Transplant Recipients, Non-functioning Pituitary Adenoma
Implementing eHealth Interventions Into Regular Clinical Practice
The purpose with this study is to test a digital patient-provider communication tool for symptom and needs management among patients with chronic health conditions.
- Trial name
- InvolveMe (NCT04218721)
- Testing
- InvolveMe
- Where
- Norway
- Volunteers
- 23 people
- Sponsor
- Oslo University Hospital